Tonix Pharmaceuticals Holding Corp. (TNXP)·Q1 2025 Earnings Summary

Executive Summary

• Q1 2025 revenue was $2.43M, down 2% year over year from $2.48M; net loss was $16.83M and GAAP diluted EPS was $2.84 loss per share . Versus S&P Global consensus, TNXP modestly missed revenue ($2.43M vs $2.55M) but beat EPS (Primary EPS actual -2.642 vs -3.23 estimate), with very limited coverage (two estimates)*.
• Cash and equivalents were $131.7M at March 31, 2025; management reiterated cash runway into Q2 2026 and noted ~$59.8M ATM proceeds in Q1 and $9.9M additional proceeds post-quarter, as well as a 150,000-share repurchase for ~$2.9M .
• Regulatory momentum is a key catalyst: FDA will not require an Advisory Committee for TNX-102 SL; PDUFA decision for fibromyalgia is scheduled for August 15, 2025, with commercial launch planning underway for Q4 2025 .
• Pipeline execution continued: positive Phase 1 results for TNX-1500, TNX-801 mpox/smallpox vaccine data presented, and first patient dosed in the OASIS Phase 2 trial of TNX-102 SL for acute stress reaction (ASR) .

* Estimates from S&P Global; see “Estimates Context” section.

What Went Well and What Went Wrong

What Went Well

• Regulatory pathway de-risked: “FDA will not require an advisory committee meeting” for TNX-102 SL; management reiterated positioning for Q4 2025 launch if approved . “We believe we are well positioned to launch TNX-102 SL for the management of fibromyalgia in the fourth quarter of 2025 if approved by the FDA.” — Seth Lederman .
• Pipeline progress: Positive topline Phase 1 results for TNX-1500 support moving to Phase 2 with monthly dosing; TNX-801 showed durable single-dose protection and tolerability in preclinical models .
• Liquidity strengthened and runway extended: Cash reached $131.7M; runway into Q2 2026 reaffirmed; incremental ATM proceeds post-quarter and share buyback demonstrate balance sheet flexibility . “Tonix believes it has sufficient cash to fund operations beyond these key milestones.” — Seth Lederman .

What Went Wrong

• Top-line softness: Net product revenue declined to $2.43M from $2.48M YoY; SG&A increased to $10.1M, reflecting commercial build and marketing investment .
• Continued operating losses: Operating loss was $16.05M and net loss was $16.83M; R&D decreased YoY but losses remain material prior to TNX-102 SL potential launch .
• Program adjustment: TNX-1300 Phase 2 CATALYST study enrollment was terminated due to slower-than-projected recruitment (not for safety/efficacy reasons), with design/endpoints under reevaluation .

Financial Results

Sequential Trend (Q3 2024 → Q4 2024 → Q1 2025)

Note: Q4 2024 “Cost of Sales” narrative references ~$1.2M; the consolidated statement shows $2.367M “Cost of revenue.” We cite the statement values where used ; narrative figure shown separately .

Year-over-Year Comparison (Q1 2024 → Q1 2025)

Margins (S&P Global values)

Values retrieved from S&P Global.
Note: Gross margin in Q1 2025 is consistent with press release arithmetic (Revenue $2.429M, Cost of Sales $0.943M) .

KPIs and Balance Sheet

Guidance Changes

Earnings Call Themes & Trends

Note: No Q1 2025 earnings call transcript was available in our document set.

Management Commentary

• “We believe TNX-102 SL…is on track to become a new therapeutic option…Our focus continues to be on the upcoming…PDUFA goal date of August 15, 2025…We are building out our commercial team for the anticipated product launch in the fourth quarter of this year.” — Seth Lederman, CEO .
• “We are pleased that FDA will not require an advisory committee meeting as part of the regulatory review process for TNX-102 SL…We believe we are well positioned to launch TNX-102 SL…in the fourth quarter of 2025 if approved by the FDA.” — Seth Lederman .
• “Addressing sleep disturbances is crucial in managing ASR…We look forward to topline results [OASIS] in the second half of 2026.” — Seth Lederman .

Q&A Highlights

• No Q1 2025 earnings call transcript was available; therefore, no Q&A summary can be provided from primary sources in this period.

Estimates Context

• EPS beat: Primary EPS actual (-2.642) vs consensus (-3.23) by ~$0.59; revenue miss: $2.43M vs $2.55M. Coverage is sparse (two estimates), which may magnify beats/misses and reduce reliability for trading models.
• Target price consensus stood at ~$67.67 (three estimates), indicating constructive long-term views among covering analysts, but this is highly sensitive to August PDUFA outcomes.

Key Takeaways for Investors

• The August 15, 2025 PDUFA decision for TNX-102 SL is the dominant near-term catalyst; absence of an AdCom reduces procedural risk and supports a pre-launch narrative into Q4 2025 .
• Liquidity is solid ($131.7M cash; runway into Q2 2026), enabling commercialization build and pipeline execution without near-term financing pressure, despite operating losses .
• Pipeline momentum (TNX-1500 Phase 1 success; TNX-801 durable protection) broadens optionality beyond fibromyalgia, offering medium-term value creation pathways .
• Commercial readiness is advancing via TONIX ONE and additions to Market Access/Technical leadership, positioning for potential TNX-102 SL launch and to support migraine portfolio revenue .
• Revenue base remains small and variable pre-approval; YoY net product revenue declined slightly and SG&A increased with launch preparation. Expect OpEx to remain elevated until regulatory outcome and launch .
• Program reprioritization is ongoing (TNX-1300 redesign after slow enrollment), reflecting disciplined capital allocation; investors should monitor updated timelines for TNX-1300 and OASIS Phase 2 readout in 2H 2026 .
• Trading implications: Expect sensitivity to regulatory headlines (label, review issues), commercial readiness updates, and any pre-launch payer/access signals; limited sell-side coverage raises the impact of incremental news flow on stock volatility.

---

Appendix: Additional Relevant Press Releases in Q1–Q2 2025

• FDA will not require AdCom for TNX-102 SL (Mar 24, 2025) .
• TONIX ONE™ digital platform launch for migraine (Apr 1, 2025) .
• Makana collaboration for xenotransplantation with TNX-1500 (Apr 9, 2025) .
• TNX-801 mpox/smallpox vaccine data at World Vaccine Congress (Apr 24, 2025) .
• First patient dosed in OASIS Phase 2 (ASR/ASD) trial (May 21, 2025) .

Appendix: Prior Quarter Summaries

• Q4 2024/FY release (Mar 18, 2025): Revenue $3.779M; net loss $22.108M; cash $98.8M; reiterated launch planning for TNX-102 SL .
• Q3 2024 release (Nov 12, 2024): Revenue $2.822M; net loss $14.213M; NDA submitted; Fast Track designated; DTRA contract affirmed .

Notes and citations:

• All quoted and tabulated figures above sourced from TNXP’s Q1 2025 8-K (press release and exhibits), Q4 2024 press materials, and related press releases .
• Margins table values marked with * retrieved from S&P Global; values may differ from simple press release arithmetic due to standardized classifications and methodologies.